[Translation] PaTHway China Trial: A randomized, double-blind, placebo-controlled, parallel-design, multicenter Phase III clinical trial evaluating the safety and efficacy of once-daily subcutaneous TransCon PTH for the treatment of hypoparathyroidism in adults sexual expansion stage)
评估 TransCon PTH 治疗 26 周后,对控制血钙(sCa)正常且停用常规治疗的有效性。常规治疗指活性维生素 D(骨化三醇)或其类似物(阿法骨化醇),联合钙补充剂>600 mg/天。
[Translation] To assess the effectiveness of TransCon PTH treatment for control of normocalcemia (sCa) and discontinuation of conventional therapy after 26 weeks of treatment. Conventional therapy refers to active vitamin D (calcitriol) or its analog (alfacalcidol), in combination with calcium supplementation >600 mg/day.